Hospitalized at Griffin Hospital in the Past 6 Years? Read This.

If you or someone you know was a hospitalized patient at Griffin Hospital between September 1, 2008, and May 7, 2014, you may be entitled to a free screening, testing, and counseling if you were administered insulin.

Insulin pens (also just called 'pens') used on hospitalized patients were potentially used inappropriately in multiple situations. The pens in question used at Griffin Hospital were allegedly equipped with a multi-dose vial of insulin. The pens are designed to be "single-person use" and are generally used to administer multiple doses of insulin to only one patient. The alleged issue with the "single-person use" pens used by Griffin Hospital between September 1, 2008, and May 7, 2014, was that cartridges of single pens may have been used to administer insulin to multiple patients, contrary to their intended purpose.

Photo Credit:

The potential risk with the alleged way that Griffin Hospital used "single-person use" pens is that even if a new needle is used every instance, the pen's cartridge is susceptible to contamination through the back-flow of blood or skin cells when the insulin is administered. If this back-flow of blood is then administered with the insulin dose to the next patient, there is a possibility of transmitting an infection in the next patient.

If you fit the criteria above, you can do the following:

  • You may be entitled to get tested for free. Griffin Hospital has opened phone lines dedicated to this issue open from 7 a.m. to 10 p.m. seven days a week. The hotline numbers are 203.732.1411 and 203.732.1340. These numbers can be called to schedule confidential testing or to answer any underlying questions you may have.
  • In the event that an infection has occurred, you should notify your doctors immediately.
  • You can seek legal counsel to see what rights, if any, you may have as a result of allegedly being infected “single-person use” insulin pens between September 1, 2008, and May 7, 2014.

Griffin Hospital has issued a statement indicating that the risk of disease transmission through the alleged use of "single-person use" pens to multiple patients is minuscule.